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Polypharmacy is often needed for the management of cardiovascular diseases and 30 
is associated with poor adherence to treatment. Hence, highly flexible and adaptable 31 
systems are in high demand to accommodate complex therapeutic regimens. A novel 32 
design approach was employed to fabricate highly modular 3D printed ‘polypill’ 33 
capsules with bespoke release patterns for multiple drugs. Complex structures were 34 
devised using combined fused deposition modelling 3D printing aligned with hot-35 
filling syringes. Two unibody highly modular capsule skeletons with 4 separate 36 
compartments were devised: i) concentric format: two external compartments for 37 
early release whilst two inner compartments for delayed release, or ii) parallel 38 
format: where non-dissolving capsule shells with free-pass corridors and dissolution 39 
rate-limiting pores were used to achieve immediate and extended drug releases, 40 
respectively. Controlling drug release was achieved through digital manipulation of 41 
shell thickness in the concentric format or the size of the rate limiting pores in the 42 
parallel format. Target drug release profiles were achieved with variable orders and 43 
configurations, hence confirming the modular nature with capacity to accommodate 44 
therapeutics of different properties. Projection of the pharmacokinetic profile of this 45 
digital system capsules revealed how the developed approach could be applied in 46 
dose individualization and achieving multiple desired pharmacokinetic profiles. 47 




1. Introduction 49 
Population-based surveys and cross-sectional studies have shown that polypharmacy affects 40-50 
50% of elderly patients in high income countries. [1-3] Among chronic conditions, cardiovascular 51 
disease (CVD) accounts for 45% of all deaths in Europe[4] and its management necessitates a 52 
complex therapeutic regimen, which usually includes anti-platelet, anti-hypertensive and lipid-53 
lowering agents.[5] Such complex treatment has been linked to many issues, including 54 
psychological distress, depressing symptoms and poor adherence among patients.[6-8] Common 55 
strategies to improve patient compliance include the use of medication boxes or technologies like 56 
PillPack dispensing system, alarms to remember dose times, medicines administration records 57 
(MARS), and smartphone applications such as My Medication Passport. [9-11] 58 
However, these approaches are usually associated with instructions that may be hard-to-read, 59 
understand and/or even follow by elderly patients. [12] Additionally, daily medication boxes often 60 
contain different unlabelled tablets/capsules that may have similar physical appearance and might 61 
lead to dispensing, patients or carers errors. Therefore, technology-based approaches need a more 62 
rigorous evaluation of cost-effectiveness and patient acceptability, suggesting that a more 63 
simplified and efficient strategy is needed.[13] Polypills can simplify the dosing regimen without 64 
compromising the therapeutic plan. The rapidly growing interest in this approach resulted in the 65 
progression of several combinations of drugs to clinical trials and registered products.[14] Despite 66 
their proven advantages, the rigid nature of fixed multiple-drug combination in a single pill may 67 
be suitable for a limited number of patients. Hence, a highly adaptable manufacturing technique 68 
that allows easy selection and titration of multiple drug doses is needed.  69 
3D printing is an emerging production method with potential superior agility in the production of 70 
on-demand medicines, with a small number of processing steps, low costs and flexibility of 71 
design. [15, 16] Several studies have reported the applicability of fused deposition modelling (FDM) 72 
3D printing in the production of solid dosage forms.[17-19] Its advantage of medicine 73 




improving characteristics such as palatability,[20] and by fabrication of a ‘dynamic dose combiner’ 75 
which can be easily shaped to each patient’s needs.[21, 22] 76 
To optimise therapeutic effect, controlling drug release from 3D printing technologies was 77 
achieved by modifying printing parameters e.g. infill percentage, [23, 24] or the shape or size of the 78 
dosage form.[25] 3D printed capsules avoid the high temperatures usually required with FDM 3D 79 
printing. An early attempt of FDM 3D printing of a pulsatile release capsule system was reported 80 
in 2015.[26]  Further studies have achieved delayed [27, 28] or pulsatile release capsules.[29] The 81 
capsules were  manufactured in two pieces to be manually assembled in a second step. Therefore, 82 
a one-step ‘print and fill’ capsule was developed.[30, 31] However, the use of water-based 83 
formulations was linked to moisture absorption by Polyvinyl(alcohol) (PVA) shells with swelling, 84 
wall delamination and leakage of the infill. Such deficiencies highlighted the need for formulation 85 
optimization of a capsule filling that was compatible with the polymeric walls. Also desirable, 86 
and explored in the current study, is a 3D printable modular system capable of including larger 87 
numbers of molecules and controlling their dissolution rate. 88 
Physiologically based pharmacokinetic (PBPK) model simulation is a tool which has been 89 
increasingly used in pharmaceutical development in order to improve efficiency and reduce costs 90 
in drug development and absorption, distribution, metabolism & excretion (ADME) assessments. 91 
It has proved useful in optimization of clinical trials design, for example in the selection of the 92 
drug dose, and helped to understand how individual variability affects drug pharmacokinetics. 93 
The simulation model has also demonstrated to be a valuable tool in clinical trials that need 94 
individualized adjustable drug doses, for example paediatric[32] and hepatically impaired 95 
patients.[33] 96 
In this study, we present a facile modular platform for individualized complex therapeutic 97 
regimens. By adopting combined hot-fill technology to produce unibody capsules of complex 98 
structure, a highly modular capsule platform with tuneable release was achieved by mere use of 99 
a modified digital design. Four model drugs were used in the development of two highly flexible 100 




shell (polylactic acid (PLA)). The second system was based on shell thickness control of a water 102 
soluble PVA shell. The in-silico simulation of pharmacokinetics of these tablets aimed to provide 103 
a means of pre-designing optimization of the pharmacokinetics of multiple drugs to suit individual 104 
patient need. 105 
2. Results and discussion 106 
Capsules of complex structure were designed to include an oval hollow geometry comprising 4 107 
compartments, where each compartment accommodated a single drug-loaded capsule filling. The 108 
compartments were configured in two design formats (parallel or concentric) to achieve different 109 
drug release patterns. Each design was split into two complementary parts: top and bottom design 110 
files (correspondent to the base and cap) (Figure 1). The design allowed for three-step 111 
manufacturing, where the base of the capsules was produced first (Figure 2A3 and 2B3), then 112 
hot-filled (Figures 2A4 and 2B4) before, thirdly, a complementary cap is printed with subsequent 113 
sealing of the capsule (Figure 2A5 and 2B5). After dispensing the identical volume of the filling, 114 
it reached similar height within the capsule. The physical isolation of each drug in a separate 115 
compartment is considered to prevent potential drug-drug interactions within the dosage form and 116 
allow for the individualization and “tuning” of each model drug’s release profile.  117 
Parallel compartments were designed into the capsular structure with different pore sizes, 118 
according to the desired release profile (Figure 1A). Internal compartments were designed with 119 
(2 mm) free-pass windows to yield an immediate release profile whilst external compartments 120 
were fabricated with rate-limiting pores to extend drug release from the capsule. Following an 121 
optimization process of pore configuration, dual pores for each side of the compartment seem to 122 
allow faster drug release than a single pore of double size (Supporting information Figures S1). 123 
The impact of pore size on drug release was also screened for all module drugs (Supporting 124 
information Figures S2). Finally, total pore surface areas of 0.25 mm2 and 0.49 mm2 for each 125 
compartment were selected to offer an extended release (Figure 1B4). The inclusion of four 126 




permitted aqueous flow within the capsule. SEM images confirmed pore walls within a range of 128 
± 60 µm of the design (data not shown). 129 
To obtain extended and delayed drug release profiles, an alternative format (concentric capsule) 130 
was devised. Two external and two internal compartments were configured to obtain extended 131 
and delayed drug release profiles, respectively (Figure 1B). A wall thickness of 0.6 mm was 132 
selected to maintain physical integrity of the capsule. By manipulating the thickness of the 133 
bottom, upper and inner walls of the two inner compartments, the design aimed to control the lag 134 
time of the delayed drug release. Capsules of different thickness of the inner wall (in multiple 135 
increments of 0.6 mm) were fabricated to probe their effectiveness in delaying drug release 136 
(Figures 2A1/2/6).  137 
In order to establish the modularity of the system to meet various patients’ needs, both design 138 
formats were configured in two drug-sequences: Sequence I, where the most soluble drugs 139 
(lisinopril and amlodipine) are dispensed in the immediate (PLA shell) or extended (PVA shell) 140 
release compartment and the least soluble drugs (indapamide and rosuvastatin) were placed in the 141 
extended (PLA shell) or delayed (PVA shell) release compartments. Sequence II, differed in that 142 
the model drugs were configured in reverse order.  143 
Liquid infill formulations are often used in capsules to improve solubility or the dissolution of 144 
poorly soluble drugs.[34] Putting a liquid formulation into a 3D printed capsule shell presents a 145 
major challenge with reported leaking issues and loss of capsule structure.[31] To establish 146 
compatibility between the infill versus the PVA and PLA 3D printed capsule shells, a fluorescent 147 
molecule was used in the hot fill process  of  a liquid formulation of PEG 400,  a commonly used 148 
solubility enhancer in soft gelatine capsules.[35, 36] Photographs of PVA concentric capsules 149 
showed the absorption of the PEG solution by the shell through time (Figure 3A). Indeed, 150 
microscopic pictures confirmed the migration of fluorescent solution through the polymeric shell 151 
in contact with the PEG solution. This could be attributed to the established miscibility of PEG 152 
400 with the PVA matrix.[37] Likely arising from the significant known plasticising effect of PEG 153 




this could lead to interference of the different drug-loaded fillings and alter the individualized 155 
release patterns of the drugs as well as initiating potential drug-drug interactions. On the other 156 
hand, PLA capsules remained visibly unchanged with PEG solution as the capsule filling (Figure 157 
3B). However, a previous study has reported the plasticising effect of PEG 400 in PLA when 158 
mixed at 90 °C. [39]  159 
To overcome this, PEG 4000 (melting temperature of 61. 5°C,) was added to allow solidification 160 
of the structure at room temperature (Figure 4E/F/G/H). The paste was engineered to solidify 161 
rapidly within the capsule compartments. Our initial screening indicated that an overall 162 
percentage of PEG blends is ideal around 40% to maintain the integrity of the shell e.g. an 163 
increased ratio of PEG 400 yielded fillings that leaked and were not compatible with the shell, 164 
while fillings with increased ratio of PEG 4000 were too slow to solidify and compromised the 165 
shell integrity (data not shown). In order to regulate the rheological behaviour during extrusion, 166 
lactose was added to the blend and yielding a facile filling paste to be hot-filled at relatively low 167 
temperature (60 °C) Thermogravimetric analysis was performed in order to assess thermal 168 
stability of the raw materials and the developed drug-loaded capsule fillings. Thermogravimetric 169 
profiles of drug-loaded capsule fillings showed continuous weight loss of about 3% up to 120 °C, 170 
which was believed to be due to evaporation of moisture in the PEG 400, PEG 4000 and drug 171 
substance (Figure 4 A/B/C/D). No significant weight loss was observed at the processing 172 
temperature (60 °C).  173 
The stability of the drug in the fill matrix was determined after 24 hrs to assess the compatibility 174 
of the model drugs at the processing conditions temperature. All individual capsule fillings 175 
showed a good stability at the processing temperatures for a period of at least 24 hrs (data not 176 
shown), a finding indicating that the composition would be compatible with a process automation 177 
using dispensing heated syringes.  178 
Considering the results of differential scanning calorimetry, the presence of the endothermic 179 
peaks corresponding to the melting of a blend of PEG 400, PEG 4000 and lactose for the drug-180 




facilitates their solidification on dispensing to the capsule shell. A broad peak is seen in both drug-182 
free and drug-loaded capsule fillings in the range of 100-150 °C, that may be explained by 183 
dehydration of lactose (Figure 4). The DSC profile for the lisinopril-loaded capsule filling 184 
suggested degradation at around 150 °C. This finding was not unexpected given the reported 185 
sensitivity of this molecule to degradation through a Maillard reaction with lactose (Figure 4E). 186 
[40]  The use of 60 °C as a processing temperature will minimise the interaction. 187 
XRD intensity patterns of the lisinopril-loaded capsule filling showed diffraction peaks 188 
characteristic of the drug substance at 2(Ɵ)= 7.5°, 12.5° and 13.6°, revealing the presence of the 189 
crystalline form of the drug (Figure 5A). The absence of characteristic diffraction peaks of 190 
amlodipine, indapamide and rosuvastatin in their correspondent capsule filling indicates that these 191 
drug substances were likely amorphous within capsule fill matrices (Figures 5B-D). This finding 192 
was consistent with DSC data, which revealed no endothermic events near the melting 193 
temperatures of any of the drugs. These findings could be partially explained by the solubility 194 
parameters values of PEG and the model drugs (Table 2). Lisinopril and amlodipine showed the 195 
highest difference in total solubility parameter value in comparison to PEG, while rosuvastatin 196 
and indapamide have solubility parameter values with a difference of <7 MPa1/2. 197 
 While PEG 400 serves as solvent, PEG 4000 and lactose were added to increase the viscosity of 198 
infill upon cooling to room temperature. Therefore, rheology studies were performed to confirm 199 
the functionality of PEG 4000 and lactose in the capsule fillings as viscosity enhancers. This will 200 
allow to assess the flowability of the filling (syringeability) at various temperatures and identify 201 
the ideal temperature for capsule filling. The viscosity of the filling was assessed at various 202 
temperatures. Complex viscosity data at the processing temperature (50 °C) are shown in Figure 203 
5E. (Attempts to assess the complex viscosity of the samples at room temperature (25 oC) were 204 
unsuccessful, due to the solid nature of the ink). The minimum temperature that allowed 205 
successful analysis was 40 °C and results can be seen in Figure 5F. The results show that PEG 206 
400 has a relatively low viscosity with minimum shear thinning behaviour (typical Newtonian 207 




pronounced shear thinning behaviour typical of thermoplastic polymers. Their mixtures exhibited 209 
a complex value in between both the pure material with shear thinning behaviour. The addition 210 
of lactose increased the complex viscosity value while maintaining the shear-thinning behaviour. 211 
In general, adding model drugs to each formulation did not have a significant effect on the 212 
complex viscosity (complex viscosity studies for other model drugs are shown in Supporting 213 
information, Figure S3).  214 
The strategy of pore fabrication via FDM 3D printing can influence drug release profiles. Initially, 215 
drug release from the capsule was attempted through inclusion of a single perforating square 216 
shape (pore), however drug release was limited. To accelerate drug release, a dual pore system 217 
was employed for each compartment. The effect on drug release was markedly evident compared 218 
to a single pore, despite having the same total area (Supporting information, Figure S1). The 219 
increase was attributed to an enhanced hydrodynamic flow through the capsule in the dual pore 220 
system, leading to accelerated media flow and a thinner dissolution layer. It is also possible that 221 
air bubbles can be entrapped within the compartment and hinder hydrodynamic flow within the 222 
compartment. Therefore, this risk was mitigated by using four rate-limiting pores per 223 
compartment.  224 
Different pore areas were then evaluated (Supporting information, Figure S2). In general, an 225 
increase in the total area pore area resulted in faster release rate of the drugs. However, controlling 226 
release by modification of the pores area proved to be more effective with indapamide and 227 
rosuvastatin, which have lower aqueous solubilities, when compared with lisinopril and 228 
amlodipine.[41-44] Total areas of 0.25 and 0.49 mm2 provided a better extended release for lisinopril 229 
and amlodipine, and indapamide and rosuvastatin, respectively. In Sequence I, lisinopril and 230 
amlodipine showed an immediate release with >80% of drug dissolved in 30 min. A total pore 231 
area of 0.49 mm2 was necessary to achieve 89% and 55% of indapamide and rosuvastatin release 232 
after 24 hrs (Figure 6A2). The effect of drug solubility was visually demonstrated by comparing 233 
with Sequence II, where the free-pass corridors allowed >80% of indapamide release only after 3 234 




rosuvastatin and indapamide which can be explained by their acidic nature (pKa of 4.2-4.6 and 236 
8.8 respectively).[45, 46] Although a 0.49 mm2 area proved to be suitable to reach extended release 237 
in Sequence I, a smaller area (of 0.25 mm2) was necessary to slow down lisinopril and amlodipine 238 
release (Figure 6B1). This illustrated the importance of software input to “tune” drug release 239 
through pore size to accommodate a wide range of model drugs of variable solubilities. 240 
Incomplete drug release was observed for indapamide and rosuvastatin in Figures 6A1/A2 and 241 
for lisinopril and indapamide in Figure 6B1, after a period of 24 hrs. This might lead to higher 242 
plasma exposure when patients have longer transit time.[47] Therefore, it is important to engineer 243 
capsules to complete drug release within the transit time of non-disintegrating oral doses.   244 
In order to achieve a chronotherapeutic effect, a concentric PVA polymeric shell was devised. 245 
The design was successful in producing extended and time-dependent delayed release (Figure 7). 246 
In general, a thickness of 0.6 mm was responsible for a lag time of 1 hr, and drugs dispensed in 247 
the external compartments achieved >75% of drug released after approximately 3 hours after the 248 
start of dissolution (Figure 7). This lag phase can be attributed to the time needed for the 249 
dissolution of the outer shell and drugs in the external compartments. The dissolution mechanism 250 
of PVA in the capsule shell is mediated mainly through erosion.[48,49] Increasing the inner, top and 251 
bottom walls thicknesses to 1.2, 1.8 and 2.4 mm resulted in a lag time of  4, 6 and 8 hrs, 252 
respectively, and >80% drug dissolution around 6 hrs thereafter (Figure 11A3/B3). External 253 
compartments (of 0.6 mm thickness) eroded at a speed of 0.6 ± 0 mm/hr, and internal 254 
compartments at 0.41 ± 0.09 mm/hr. The suitability of the polypills was demonstrated using four 255 
clinically relevant drugs for the treatment of CVD, however its application to other therapeutic 256 
regimens is unlimited. The high versatility of the system is expected to be associated with 257 
improved clinical outcomes, by customization of the release profile of drugs to target specific 258 
times to attain peak plasma concentration and to avoid drug-drug interactions in complex 259 
therapies. One limitation of the developed capsule systems is its relatively large size and shape. 260 




applied to meet FDA guidance for recommended size and shape in order to improve patient 262 
acceptability. [50] 263 
In the clinical setting, bespoke dosage forms can be dispensed as a patient-specific medicine in 264 
an extemporaneous setting. Initial stability trials to determine the impact of storage conditions of 265 
the developed capsules were conducted over 28 days. In general, no physical change of the 266 
capsule structure was observed by visible inspection (Supporting information, Figure S4). 267 
Lisinopril and rosuvastatin did not show significant (p>0.05) degradation when stored at 4°C 268 
(Supporting information, Table S1), while a decrease in drug content was significant (p>0.05) 269 
for indapamide and amlodipine when in PLA capsules. This may be explained by a protective 270 
effect of the PVA shell on moisture. The highest degree of degradation of amlodipine when 271 
compared with the rest of the model drugs may be due to the high sensitivity of this drug molecule 272 
to moisture and light.[51,52] It is possible that the open pores within the architecture of the parallel 273 
design favoured the penetration of light and moisture and contributed to higher level of 274 
degradation in amlodipine chamber. In general, immediate release chambers yielded similar 275 
release pattern, whilst extended and delayed release patterns was more sensitive to storage 276 
temperature (Supporting information, Figures S5 and S6). 277 
To project the clinical implication of using this bespoke drug delivery system for cardiovascular 278 
system, a simulation absorption model was developed to study the  effect of drug 279 
dissolution in drug pharmacokinetics. Validation of the developed models was performed by 280 
comparison of the simulated AUC, Cmax and Tmax with the observed clinical studies (Supporting 281 
information, Table S2). PLA-based capsules showed a clear predictable effect of drug 282 
dissolution in the pharmacokinetics profile. Cmax was proportional with the maximum drug release 283 
achieved from the in vitro dissolution studies (Figure 8 and Supporting information, Figures 284 
S7). PVA-based concentric capsules with different wall thicknesses showed similar good 285 
correlation with Cmax values and Tmax values proportionally increasing with the drug release time 286 
(Figure 9 and Supporting information, Figures S8). Pharmacokinetic parameters values 287 




and S4, respectively. The ease of modelling the results highlights the applicability of such a 289 
highly modular drug delivery systems to conveniently produced timed drug dose release with 290 
“tuned” peak drug plasma concentrations to achieve optimal clinical outcome.  291 
We envisage the employment of such digitised and modular system as part in an integrated 292 
healthcare network in the future (Figure 10). In such a configuration, patient’s data and genomics 293 
will feed an artificial intelligent and big data-powered network, where desired target PK profile 294 
can be set, tested and refined in multiple cycles to achieve clinical outcome in seamless fashion. 295 
The growth of database and number of participants in such integrated system to a critical mass 296 
can potentially revolutionise and transform the efficacy, safety and patient-centricity of multiple 297 
drug treatments. 298 
3. Conclusions 299 
We present a highly modular multi-compartmental capsule platform of complex structure that 300 
accommodates 4 model drugs for bespoke dosing and drug release. A specially developed rapid 301 
solidifying fill matrix proved compatible with two biodegradable polymeric shells (PVA and 302 
PLA). Two architecture formats, based on digital manipulation of wall thickness and pore sizes, 303 
allow a customised release profile for each drug molecule. The novelty of this system resides in 304 
employing an established additive manufacturing method with liquid dispensing to achieve a 305 
complex multidrug releasing dosage form starting from identical materials. Hence, the platform 306 
enables serving large number of patients with a small number of starting materials and relatively 307 
low costs. The approach yields minimal migration of the formulation through the shell structure 308 
and is stable for 28 days following production (comparable to the usual shelf-life for 309 
extemporaneous preparations). While this work provides a proof-of-concept for 4 drug molecules, 310 
the reported platform can easily be generalised to a wider spectrum of drug substances that are 311 
frequently prescribed together. This work showcases a powerful and economical approach of 312 




accommodate the increasing number of patients who receive multiple and complex dosing 314 
regimens.  315 





4. Experimental Section 318 
 Materials:  Lisinopril dihydrate, amlodipine besylate, indapamide and rosuvastatin calcium 319 
were obtained from Kemprotec Ltd (Cumbria, UK). HPLC gradient grade acetonitrile and 320 
methanol were from Fisher Scientific Ltd (Loughborough, UK). Dipyridamole, poly(ethylene 321 
glycol) (PEG) 4000 and alpha-D-Lactose monohydrate ACS reagent grade were purchased from 322 
Thermo-Fisher Scientific (UK). Poly(ethylene glycol) (PEG) 400 was from Merck KGaA 323 
(Darmstadt, Germany). Polyvinyl alcohol (PVA) and Poly(lactic acid) (PLA) filaments were 324 
obtained from MakerBot® Industries (NY, USA). All other chemicals were of analytical grade.  325 
 326 
Preparation of the capsule fill matrix: A rapid solidifying shell-compatible hot-fill fluid was 327 
developed.  The composition of each drug-loaded fill matrix is detailed in Table 1.  The filling 328 
was prepared by dissolving accurately weighed model drug in PEG 400 in a beaker and sonicating 329 
the solution/suspension for 15 min. PEG 4000 was then incorporated in the mixture, which was 330 
then heated in a FD240 binder heating chamber (Tuttlingen, Germany) for 1 hr at 60°C. Following 331 
the complete melting of PEG 4000 and mixed, lactose was suspended and manually mixed to 332 
obtain a uniform paste. Pastes were then maintained at 50°C. A volume of 80 µL (~100 mg) of 333 
each model drug fill matrix was manually dispensed in each capsule compartment using a 1-mL 334 
GASTIGHT® syringe (Hamilton Company, UK) equipped with a 18 gauge- 6.35 mm length 335 
needle (McMaster-Carr, CA, USA).  336 
 337 
3D printing of capsules: Capsule shells of innovative complex architecture were designed using 338 
Autodesk® 3ds Max Design 2016 software version 18.0 (Autodesk, Inc., USA). An oval shape 339 
was chosen to simplify its division into 4 compartments with similar volumes. The capsules (with 340 
0.6 mm walls) were designed with a standard size of 24.1 x 15.1 x 6.26 (X x Y x Z) mm. PVA 341 




thickness of 1.2, 1.8 and 2.4 mm respectively. Two design formats (Figure 1) were adopted to 343 
couple extended or delayed release patterns for two model drugs with immediate or extended 344 
release for the other two model drugs: 345 
1. PLA-based parallel design capsules with immediate release and extended release 346 
architecture (Figure 1A). Internal compartments were designed with free-pass corridors 347 
(2 mm) to facilitate free access of dissolution media and subsequent rapid dissolution and 348 
release of capsule fillings. External compartments were designed with rate-limiting pores. 349 
The optimization of the design was performed by assessing the release profile of the drugs 350 
using a different number (two or four) of the rate-limiting pores per compartment and 351 
different total pore areas (namely, 0.25, 0.49, 0.72 and 1mm2). After optimization, the 352 
design with four pores per external compartment (two on each side) and pores areas of 353 
0.25 and 0.49 mm2 were selected as a default. 354 
2. PVA-based concentric design capsules with variable shell thicknesses (Figure 1B) with 355 
extended and delayed release system architecture. External walls of the capsule were 356 
designed with a 0.6-mm thickness to provide an extended release. Capsules with top, 357 
bottom and internal walls were designed with various wall thicknesses (namely 0.6, 1.2, 358 
1.8 or 2.4 mm) in order to achieve a delayed drug release profile from the internal 359 
compartments.  360 
Each design was split into two complementary objects: base and cap. 3D printing of both capsule 361 
formats was done using a Makerbot Replicator 2X (Makerbot Industries, LLC, USA) at nozzle 362 
and platform temperatures of 200 °C and 50 °C, respectively. Capsule shells were divided in two 363 
stereolithography (.stl) files format correspondent to the base and cap of the capsule. 3D printing 364 
of the capsule shells was performed without using removable supports and took a maximum of 365 
10 min.  Each capsule was fabricated in three steps: i) 3D printing of the bottom portion of the 366 
design (base), ii) manual capsule filling as detailed in the previous section, and iii) 3D printing of 367 




printing plate and at z-level equivalent to the height of the complementary base. No additional 369 
sealing materials or process were used in the process.  370 
Compatibility of the hot-filling matrix with the capsule shell: Fill-matrix compatibility with PLA 371 
and PVA shells was studied by assessing the developed fast solidifying fills using a fluorescent 372 
molecule (dipyridamole). Capsule fillings (as described above) and dipyridamole solution in PEG 373 
400 (control) were dispensed in PLA and PVA capsules and visualised in a NOVEX B-range 374 
microscope after 0, 0.5, 2 and 24 hrs. Samples were prepared using the concentration 375 
correspondent to the model drug with lowest dose (indapamide), 31.25 mg/mL and 2.5% for the 376 
PEG 400 and capsule filling samples, respectively. The capsules were kept at room temperature 377 
throughout the experiment and images were obtained using Image focus v3.0.0.1 software to 378 
visualise integrity. 379 
High performance liquid chromatography (HPLC):  Drug content and dissolution tests samples 380 
were analysed by HPLC, using a method that has been described in a previous study.[53] 381 
Thermal analysis: Thermogravimetric analysis (TGA) analysis was performed on a TGA Q500 382 
(TA Instruments, Elstree, Hertfordshire, UK) and samples of the raw materials and the capsule 383 
fill matrix were run in triplicate. Each sample (approximately 10mg) was heated at a rate of 384 
10 °C/min from 25 to 500 °C with a nitrogen purge of 40:60 mL/min for sample: furnace 385 
respectively. Differential Scanning Calorimetry (DSC) analysis was conducted on a DSC Q2000 386 
(TA Instruments, Elstree, UK). Samples (~10 mg) of the raw materials and the capsule fill matrix 387 
were analysed in triplicate using T-zero hermetic pans. Each sample was scanned from −50 to 388 
200 °C at 10 °C/min using a nitrogen purge of 50 mL/min. Data obtained from both TGA and 389 
DSC were analysed with TA Universal analysis software v4.5A (TA Instruments, Elstree, UK). 390 
  391 
Powder X-ray diffractometry (XRD): Powder XRD analysis of the raw materials and capsule 392 
filling was carried out using an X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, 393 




time count. The divergence slit and scatter slit were 1 mm and 0.6 mm, respectively. The 395 
wavelength of the X-ray was 0.154 nm using a Cu source, a voltage of 30 kV and a filament 396 
emission of 10 mA. 397 
 398 
Rheological studies of the capsule fill matrix: Rheology studies were performed on the capsule 399 
fills using an Anton Paar Shear Rheometry Physica MCR 301 (Graz, Austria) with 25mm parallel 400 
plates, using a 0.5mm gap distance in oscillation mode. Linear viscoelastic region (LVR) was 401 
studied with 0.5% strain amplitude. Samples were tested in triplicate using an amplitude sweep 402 
at an angular frequency range from 0.1 to 100 rad/s and angular frequency of 10 rad/s. 403 
Temperatures were set at 40 and 50°C (dispensing temperature) and readings were collected every 404 
5 sec. 405 
Solubility parameter: Hansen solubility parameters were calculated using HSPiP v5.0.08 406 
software. The canonical simplified molecular-input line-entry system (SMILES) of the 407 
compounds as stated in PubChem database  was used to calculate the solubility parameters using 408 
group contribution method [54]. It is worth noting that PEG 400 and PEG 4000 have identical 409 
SMILES and therefore have identical solubility parameter values. 410 
Stability assessment: The stability of the developed formulation was assessed in terms of 411 
compatibility with the capsule shells, drug content and dissolution profile. The drug content 412 
(w/w%) of each capsule filling was calculated by comparing the recovered amount with the 413 
theorical amount. 414 
Stability at processing conditions: Stability of the model drugs at the processing conditions was 415 
analysed. Drug content was assessed by heating the drug-loaded capsule fillings at 50 °C in a 416 
FD240 Binder heating chamber (Tuttlingen, Germany). Samples were collected at the time points 417 
0 and 24 hrs, filtered through an Econofltr 0.2 µm syringe filter (Agilent Technologies Ltd., 418 




a. Accelerated stability study: Accelerated stability of the 3D printed capsules (Sequence I 420 
PLA-based capsules with 0.49 mm2 pores and Sequence I PVA-based capsules with 1.8 421 
mm wall thickness) was performed according to ICH guidelines for one month, at 4 °C, 422 
30 °C/ 65% RH and 40 °C / 75% RH. Capsules were individually stored in high-density 423 
polyethylene bottles and analysed in triplicate in terms of visual assessment of physical 424 
capsule structure, drug content and dissolution profile (see above). For drug content 425 
analysis, PVA capsules were placed in 800 mL of water and sonicated until complete 426 
dissolution, followed by the addition of 200 mL of acetonitrile and further sonication for 427 
1 hr. PLA capsules were firstly dissolved in 200 mL of acetonitrile followed addition of 428 
800 mL water and sonication for 1 hr. For amlodipine analysis, 1 mм EDTA was added 429 
the solution. The solutions were then filtered through an Econofltr 0.2 µm syringe filter 430 
(Agilent Technologies Ltd., Cheadle, UK) and analysed by HPLC as described above. 431 
Scanning electronic microscopy (SEM) The thickness of the inner wall of the PVA concentric 432 
capsules and the pores of the PLA capsules were analysed with a JCM-6000 plus NeoScope™ 433 
microscope (Jeol, Tokyo, Japan) at 10 kV. Prior to imaging, samples were gold coated under 434 
vacuum for 2 min with a JFC-1200 Fine Coater (Jeol, Tokyo, Japan).  435 
In vitro dissolution tests. The dissolution tests for 3D printed capsules were performed on an 436 
Erweka DT600 USPII dissolution test apparatus (Heusenstamm, Germany). The tests were run at 437 
37 °C with a paddle rotation speed of 50 rpm, under sink conditions. The capsules were tested in 438 
750 mL of 0.1м HCl (pH 1.2) for 2 hrs, followed by pH 6.8 phosphate buffer for 4 hrs (with 439 
addition of 250 mL of tribasic phosphate solution 0.215 м) and then pH 7.4 phosphate buffer for 440 
additional 18 hrs. The paddles and the water bath were sealed with PTFE-coated glass cloth 441 
adhesive tape (Viking Industrial Products, Keighley, UK) and foil, respectively, and the 442 
dissolution assessment was performed in a dark room, to prevent degradation of amlodipine. Each 443 
experiment was performed in repetitions of six and samples were manually collected (4 mL), 444 
which was replaced and filtered with an Econofltr 0.2 µm syringe filter (Agilent Technologies 445 




12 and 24 hrs and analysed by the developed HPLC method previously described. The period of 447 
24 hours was selected based on average transit time of non-disintegrating tablet in the 448 
gastrointestinal tract.[55] 449 
With the assumption that a detectable drug concentration is reached when the capsule wall is 450 
completely dissolved, the erosion rate (mm/hrs) was estimated using the following equation:   451 
 452 
Erosion rate = d (mm)/ t lag (hrs) 453 
Where (d) is the thickness of the wall, and (t lag) is the lag time before the onset of drug release 454 
In silico simulation The absorption profile simulation for each drug was developed using 455 
Gastroplus® v9.7 (Simulation Plus, Lancaster, CA, USA). For the ‘compound’ and 456 
‘pharmacokinetics’ models, input data included experimental data (dissolution profile, 457 
permeability and solubility) and data obtained from literature. When precise compound 458 
parameters values were not available, parameter estimation was performed by the software. 459 
Human physiology under fasted state mode was designated and default values were used. 460 
The physicochemical properties and ADME parameters for each drug were obtained from 461 
literature (Supporting information, Table S5).  462 
Statistical analysis Statistical analysis of the results was done with independent t-test using SPSS 463 
software (22.0.2). Differences in the results below the probability level of p<0.05 were considered 464 
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Figure 1 Schematic images of PVA capsules with increased thickness of (A1) inner wall and (A2) base and cap layers. Images of the PVA concentric design 
capsules (A3) 3D printed base, (A4) capsule filling, (A5) sealed capsules. (A6) SEM images of the inner wall with increased thickness. Images of PLA parallel 
design capsules (B1) printed base, (B2) capsule filling, (B3) sealed capsules. Detailed images and correspondent SEM pictures of rate-limiting pores with (B4) 








Figure 2 Rendered images of computer-aided design (CAD) (Autodesk 3DS Max) of capsule base and cap of (A) PVA capsules of concentric compartments 
















Figure 5 Powder XRD patterns of raw materials and capsule filling of (A) lisinopril, (B) amlodipine, (C) indapamide and (D) rosuvastatin. Complex viscosity 












Figure 7 In vitro drug release of PVA concentric design capsules with (A1 and B1) 0.6 mm, (A2 and B2) 1.2 mm, (A3 and B3) 1.8 mm and (A4 and B4) 2.4 

















Figure 10 Schematic diagram of future scenario for integrated electronic healthcare system that employ Pharmaceutical 3D printer. The patient’s medical 
information and genomic specifics will be fed in artificial intelligence system, where target PK simulation will be set. Computer software will help to generate 
an in vitro plasma profile and a tailored ‘polypill’ design will be built. Healthcare team will approve a corresponding e-prescription and a personalised polypill 
will be 3D printed and dispensed to the patient. The PK data from patients to improve and maintain target plasma exposure of multiple drugs. The increased 





Table 1. Composition of hot-filled capsule contents. 







PEG 4000 PEG 400 Lactose 
monohydrate 
Lisinopril dihydrate 10% - - - 10% 30% 50% 
Amlodipine besylate - 5% - - 10% 30% 55% 
Indapamide - - 2.5% - 10% 30% 57.5% 
Rosuvastatin calcium - - - 10% 10% 30% 50% 
 
Table 2. Solubility parameters in MPa1/2 and components. 
 
Compound   Solubility parameters  
 δD δP δH δT  
Rosuvastatin 18.7 11.8 10 24.3 
Lisinopril 17.1 8.2 9.1 21 
Indapamide 21.6 18.9 9.6 30.2 
Amlodipine 18 4.3 7.2 19.8 
  PEG  19.5  13.1  20.3  31  
 
